4.5 Article

Acute respiratory distress syndrome

期刊

CLINICAL MEDICINE
卷 17, 期 5, 页码 439-443

出版社

ROY COLL PHYS LONDON EDITORIAL OFFICE
DOI: 10.7861/clinmedicine.17-5-439

关键词

Acute respiratory distress syndrome; acute respiratory failure; ARDS; critical illness; ventilator-associated lung injury

资金

  1. GSK
  2. Pfizer
  3. BI
  4. Peptinnovate
  5. Silence Therapeutics
  6. Cell Catapult

向作者/读者索取更多资源

Acute respiratory distress syndrome is a common cause of acute respiratory failure that is underdiagnosed both inside and outside of intensive care units. Progression to the most severe forms of the syndrome confers a mortality rate greater than 40% and is associated with often severe functional disability and psychological sequelae in survivors. While there are no disease-modifying pharmacotherapies for the syndrome, this progression may be prevented through the institution of quality improvement measures that minimise iatrogenic injury associated with acute severe illness.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据